Deep Dive: CVRM Masterclass From Evidence to Implementation

Name: Deep Dive: CVRM Masterclass From Evidence to Implementation
SKU: 8751
Availability: InStock

This meeting has been organised by CliniLink Ltd and is supported through sponsorship which covers the costs of the meeting including subsistence. The sponsors Daiichi Sankyo, Pfizer, Novo Nordisk, were not involved in the development of he agenda and have had no influence over the agenda, the speakers or the contents of the meeting.
See Sponsors below

£0.00

Please log in to book this event

Sponsor This Event

FACE TO FACE EVENT

THIS EVENT IS OPEN TO UK REGISTERED HEALTHCARE PROFESSIONALS ONLY

Location: Ramside Hall, Carrville, Durham DH1 1TD

Event Agenda

Time	Topic	Speaker
09:30-09:50	Registration, Networking and Coffee
09:50-10:00	Introduction and welcome	Beverley Bostock and Professor Ahmet Fuat
10:00-10:45	Managing Heart Failure in Primary Care – beyond the QoF tick box	Professor Ahmet Fuat
10:45-11:15	Sponsored session	TBC
11:15-11:30	Break
11:30-12:15	CKD – managing the under recognised risk	William Burlace
12:15-13:00	Changing the Hypertension Paradigm - the West Yorkshire guidance	Emily Turner
13:00-13.45	Lunch
13.45-14:15	Sponsored session	TBC
14:15-15:15	Implementing new NICE diabetes guidance in primary care	Beverley Bostock and Doha Ben-Hamed
15:15-15-30	Break
15:30-16:15	Simplifying Lipid management in Primary Care	Prof Ahmet Fuat
16:15-16:30	Q&A – ask anything CVDRM related	Beverley Bostock and Professor Ahmet Fuat

Why Should Healthcare Professionals Attend?

Cardiovascular–renal–metabolic (CVRM) disease is a leading cause of morbidity and premature mortality in the UK. Heart failure, CKD, type 2 diabetes, and ASCVD are closely interconnected, yet often managed in isolation.

This face-to-face study day provides a practical, NICE-aligned update on integrated CVRM management. Through expert-led, case-based discussions, delegates will gain confidence in risk stratification, treatment optimisation, and safe prescribing across the CVRM spectrum.

Learning Objectives

By the end of the study day, participants will be able to:

Apply an integrated approach to CVRM risk assessment
Optimise RAAS inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and lipid therapy
Manage complex multimorbidity, including HFrEF and CKD
Deliver prevention-focused, holistic reviews that improve long-term outcomes

Key Benefits

Practical application of NICE guidance
Clear decision-making frameworks
Improved confidence in CVRM prescribing
CPD certificate for revalidation

Additional Information

Face-to-face, CPD-accredited event.
Suitable for GPs, prescribing pharmacists, nurses, and primary care MDT members.

Meet the Speakers

Professor Ahmet Fuat

PhD, FRCGP, FRCP, FRCPE ,FESC, FPCCS, PGDiP Cardiology

Professor Ahmet Fuat was a GP in Darlington, County Durham for 40 years, where he was CVD and Research Leads for Darlington Primary Care Network and Darlington GP Federation. He was Oberoi Consulting Medical Director from September 2023 to February 2026, is National Programme Director at Clinilink Ltd and has also worked as an Honorary Consultant Lipidologist/GPSI within the diabetes and endocrinology team at County Durham and Darlington Foundation Trust, running a secondary prevention and genetic lipid clinic. He has been a GPSI Cardiology for over 25 years having undertaken a Postgraduate Diploma in Cardiology at Bradford University graduating with distinction. He went on to be a tutor on the course for many years teaching on HF, HVD, AF and IHD. He started the first one stop diagnostic and integrated heart failure clinic in the UK in 2002 with local colleagues.His PhD by research in heart failure diagnosis and management including work on natriuretic peptides generated several publications that have informed guidelines and led to the award of an Honorary Professorial Chair at Durham University. He has contributed to various NICE and ESC CVD and HF guidelines, and RCGP CKD/AKI toolkit. He has a passion for medical education and remains an active lecturer, tutor and researcher. He is on the editorial boards of the British Journal of Cardiology and Primary Care Cardiovascular Journals and a peer reviewer for most high impact Cardiovascular journals and research bodies. His work in community cardiology has been recognised with Fellowships from the RCGP, RCP London and RCP Edinburgh, ESC and the PCCS.He has led many quality improvement initiatives over the years in HF, AF, Lipids, hypertension, diabetes and CKD. His work on HF was included in their BHF blueprint for HF. Much of this work was carried out using Oberoi digital audit platforms as has been replicated by colleagues across the UK, benefiting patients and practices positively.

Beverley Bostock

RGN, MSc, MA, QN

Bev is an Advanced Nurse Practitioner in long-term conditions. She is currently President Elect of the Primary Care Cardiovascular Society. She has a special interest in cardiovascular disease (CVD), diabetes, heart failure, chronic kidney disease and lipid management along with common comorbidities such as metabolic liver disease, asthma and COPD. She is Editor in Chief of Practice Nurse Journal and has been a Queen’s Nurse since 2015. In a previous role she developed and delivered accredited modules in cardiovascular disease, heart failure and diabetes in collaboration with the Open University. As well as holding an MA in Medical Ethics and Law and an MSc in Respiratory Care, Bev is currently completing an MSc in Diabetes Care with the University of Warwick. Bev has had an extensive range of articles published in various journals on the management of long-term conditions and is a regular speaker at national conferences.

Emily Turner

Emily Turner is the Lead GP Practice Pharmacist for a large practice in Leeds, with a special interest in cardio-renal disease. She has also held the role of West Yorkshire Clinical Lead for CVD Prevention, collaborating across the West Yorkshire Health and Care Partnership to enhance cardiovascular health outcomes. In this capacity, Emily has demonstrated extensive evidence in addressing and reducing health inequalities throughout the system. On a national level, Emily contributes as a member of the England CVDPREVENT Audit Clinical Panel, the National Atrial Fibrillation Expert Advisory Group, and as a Clinical Educator for the Royal Pharmaceutical Society. As an accomplished speaker, she offers valuable expertise and practical guidance to clinicians working in primary care.

Doha Ben-Hamed MPharm IP

MPharm IP

Doha is a senior clinical pharmacist, independent prescriber, and senior lecturer in clinical pharmacy, working across the North East. She has a specialist interest in cardiovascular, renal, and metabolic (CVRM) health within diabetes care and leads on medicines optimisation, clinical education, and system‑wide improvement. Doha is currently undertaking a postgraduate diploma in diabetes, further strengthening her expertise and her commitment to supporting multidisciplinary teams to deliver high‑quality, evidence‑based care for people living with diabetes.

William Burlace

I am clinical pharmacist with over 10 years experience in both community pharmacy and primary care, graduating from the University of Sunderland in 2013. Since completing my independent prescribing at the University of Salford in diabetes and running review clinics, I have specialised more specifically in CKD and general renal medicine. I am currently one of the lead pharmacists on a ICB wide CKD project looking to improve patients' outcomes and raise awareness and improve education in CKD. I am also a board member of the NENC Renal Network, working to solidify relations between secondary care, primary care and the pharmacy sector.

Working to improve patient outcomes, particularly in underserved communities, is a real passion of mine and the importance of close neighbourhood working and education plays a vital role in this.